IndustryCompany release

Lakefront Biotherapeutics launches second €50m share buyback after completing first programme

Lakefront Biotherapeutics · Mon 16 Nov 2026

The Euronext- and NASDAQ-listed company will repurchase up to €50 million of its own shares through Morgan Stanley, with the programme running to 31 March 2027 at the latest.

Lakefront Biotherapeutics NV (Euronext and NASDAQ: LKFT) announced on 16 November 2026 a new share buyback of up to €50 million, or up to 4,604,550 shares. The programme will run until 31 March 2027 at the latest.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release: Lakefront Biotherapeutics ↗

Article written by VigiEye from the official source (Lakefront Biotherapeutics). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →